Andrew Thompson
President & Chief Executive Officer, Co-Founder
Mr. Thompson is President, Chief Executive Officer and co-founder of
Proteus Biomedical and has led the company since inception. He is also a
Managing Member of Spring Ridge Ventures, the financial founder of Proteus.
From 1994-1999, Mr. Thompson co-founded and served as a Director and Chief
Executive Officer of FemRx until the company was acquired by Johnson &
Johnson. Previously, Mr. Thompson co-founded and was Chief Financial
Officer for CardioRhythm through its acquisition by Medtronic. He holds an
M.A. in engineering from Cambridge University, where he was a United Kingdom
National Engineering Scholar, an M.A. in education from Stanford
University and a M.B.A. from Stanford University Graduate School of Business.
Proteus Biomedical Company Description:
Proteus, headquartered in Redwood City, California, was founded with a passion for improving the lives of people with chronic disease. The company is developing intelligent medicine products internally and in partnership with device, pharmaceutical and biotechnology companies. These products address therapeutic areas where disease management complexity, patient monitoring requirements, therapeutic efficacy, and poor patient adherence create large clinical and commercial opportunities. The company currently has three products in development that target cardiac disease and heart failure, including a program in Cardiac Resynchronization Therapy in partnership with a world-leader in cardiovascular implantable devices.
Proteus is a privately-held company with investors including Adams Street Partners, Asset Management, The Carlyle Group, Essex Woodlands, Fletcher Spaght Ventures, L.P. (FSV), Kaiser Permanente Ventures, and Spring Ridge Ventures.